Skip to content
OpenCapital
Get started

Pfizer PFE Acquired in-process research and development

Acquired in-process research and development at other companies

Eli Lilly logo
Eli LillyLLY
$584M-62.8%

Segments

By segment

See full
Biopharma$137M+1,422%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Questions, answered.

What does acquired in-process research and development mean?
Expenses recognized upon the acquisition of external research and development projects that have not yet reached regulatory approval or technological feasibility. These costs represent the upfront investment in future pipeline assets acquired through business combinations.